Emond Claude, Charbonneau Michel, Krishnan Kannan
Groupe de recherche en toxicologie humaine (TOXHUM), Faculté de médecine, Université de Montréal, Montréal, Québec, Canada.
J Toxicol Environ Health A. 2005 Aug 27;68(16):1393-412. doi: 10.1080/15287390590956551.
This study aimed to develop a physiologically based model for simulating the concentrations of polychlorinated biphenyls (PCBs) in tissue and plasma lipids of rats exposed to PCB mixtures. The model was based on the assumption that the neutral lipid fraction is the only critical determinant of the tissue distribution of PCBs, and that the solubility/retention in other tissue components is negligible. The volumes of the model compartments reflected the volumes of neutral lipids, whereas the flow rates corresponded to those of the neutral lipids in blood. Since the equilibrium ratio of PCB concentrations in neutral lipids of tissues and plasma equals 1, the present modeling approach does not require the use of tissue:blood partition coefficients. Metabolism rates were derived from the best visual fit of the model to the PCB concentrations in hepatic lipids determined on d 41 and 90 in rats exposed to a mixture containing 5, 50, or 500 microg PCBs (118, 138, 153, 170, 180 and 187) per kilogram body weight according to various protocols: (a) every-day dosing, (b) once-a-week dosing, (c) consecutive dosing for 13 d with no further treatment, and (d) 13 irregularly spaced doses. The resulting model consistently simulated the concentrations of PCBs in adipose tissue and plasma lipids of rats exposed according to the four described protocols. The physiologically based pharmacokinetic (PBPK) model developed in this study should be useful as a basis for interpretating blood or plasma lipid concentration data on PCBs collected during biomonitoring studies.
本研究旨在建立一个基于生理学的模型,用于模拟暴露于多氯联苯(PCBs)混合物的大鼠组织和血浆脂质中多氯联苯的浓度。该模型基于以下假设:中性脂质部分是多氯联苯组织分布的唯一关键决定因素,且在其他组织成分中的溶解度/滞留量可忽略不计。模型隔室的体积反映了中性脂质的体积,而流速则与血液中中性脂质的流速相对应。由于组织和血浆中性脂质中多氯联苯浓度的平衡比等于1,因此本建模方法无需使用组织:血液分配系数。代谢率是通过将模型与根据不同方案暴露于每千克体重含5、50或500微克多氯联苯(118、138、153、170、180和187)混合物的大鼠在第41天和第90天测定的肝脏脂质中多氯联苯浓度进行最佳视觉拟合得出的:(a)每日给药,(b)每周一次给药,(c)连续给药13天且不再进行进一步治疗,以及(d)13次间隔不规则的剂量。所得模型一致地模拟了根据上述四种方案暴露的大鼠脂肪组织和血浆脂质中多氯联苯的浓度。本研究中建立的基于生理学的药代动力学(PBPK)模型应有助于解释生物监测研究期间收集的多氯联苯血液或血浆脂质浓度数据。